Print

ANDA Litigation Settlements

Case Name

Drug

Patent No(s).

Publicly Available Terms

Abbott Labs. v. Teva Pharma. USA Inc., 10-0057, 10-0766, 11-0239, 11-0712 (D. Del.)

Simcor® (simvastatin niacin extended-release)

6,080,428

6,129,930

6,406,715

6,469,035

6,676,967

6,746,691

6,818,229

7,011,848

N/A

Medicis Pharma. Corp. v. Perrigo Co., Inc., 11-4963 (S.D.N.Y.)

Loprox® Shampoo (ciclopirox)

7,981,909

N/A

Sunovion Pharma. v. Dey Pharma., 06-0113 (D. Del.)

Xopenex® (levalbuterol hydrochloride)

5,362,755

5,547,994

5,760,090

5,844,002

6,083,993

6,451,289

Mylan may continue selling levalbuterol hydrochloride;

Mylan receives a royalty-bearing license to sell a nonconcentrate version of the generic drug, following FDA approval.

Endo Pharma. Inc. v. Watson Labs. Inc., 10-0138, 11-0575 (D. Del.)

Lidoderm® (lidocaine transdermal)

5,741,510

6,096,333

6,096,334

5,827,529

Watson may launch its generic product on Sept. 15, 2013, if approved by the FDA;

Watson will have an exclusive license to market an authorized generic until the arrival of a third party or until 7.5 months after Watson’s launch;

Endo will take 25% of the gross profit from Watson’s sales during the company’s period of exclusivity;

Watson will get approximately $96 million worth of branded Lidoderm to sell during the first 8 months of 2013;

If Watson does not get FDA approval by January 2014, it will receive $80 million worth of Lidoderm in 2014 over a period of 12 months;

If Watson does not get FDA approval by January 2015, it will receive $64 million worth of Lidoderm in 2015 over a period of 9 months.

Mylan Pharma. Inc. v. Sebelius, 12-0524 (D.D.C.)

Provigil® (modafinil)

RE37,516

“Pursuant to its agreement with Teva, Mylan is permitted to launch its generic product on Aug. 10, 2012, which is prior to the expiration of the 180-day marketing exclusivity period granted to Teva.”

Pfizer Inc. v. Teva Parenteral Medicines Inc., 10-0037 (D. Del.)

Zyvox® (linezolid for injection)

5,688,792

Teva conceded ongoing validity of the ’792 patent;

Teva agreed not to sell a product under its ANDA unless authorized by the parties’ licensing agreement.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.